How Environmental Pollutants and Genetics Work Together in Rheumatoid Arthritis

New research documents how chemicals and a certain gene activate an enzyme to increase the risk and severity of RA and bone destruction.

1:00 PM

Author | Rosemary Clandos

It has been known for more than three decades that individuals with a particular version of a gene — human leukocyte antigen (HLA) — have an increased risk for rheumatoid arthritis.

MORE FROM THE LAB: Subscribe to our weekly newsletter

Meanwhile, in recent years, there has been a growing interest in the relationship between rheumatoid arthritis and environmental factors, such as cigarette smoking. In smokers who develop rheumatoid arthritis, the disease hits harder. Smokers who also carry the HLA gene variant have even higher likelihood to develop RA, and their disease is more severe. For these patients, this means not only greater pain and swelling, but also more severe bone destruction — a lesser known and more dangerous aspect of the disease.

In a new mouse study, Michigan Medicine researchers probed the relationship between these two factors: the HLA gene and environmental pollutants.

"We found a particular enzyme that acts as a channel, or pathway, in the cell for a conversation between the two culprits, so they work together to do greater damage. Individually they are bad, but together, they're worse," says Joseph Holoshitz, M.D., professor of internal medicine and associate chief for research in the Division of Rheumatology at the University of Michigan School of Medicine.

The work is published in the Proceedings of the National Academy of Sciences

By understanding the mechanisms, we may be able to develop better inhibitors to prevent disease and identify therapeutic targets for new treatment strategies.
Joseph Holoshitz, M.D.

Factors at work

Cigarettes are one of the top environmental concerns with rheumatoid arthritis. But many other environmental pollutants can also help trigger the condition. For example, living in urban areas or near highways is linked with RA, regardless of cigarette use.

The chemical dioxin may be to blame. It's the same contaminant that was found in soil near a Dow Chemical plant in Midland, Michigan. "One scenario is that air pollution from vehicles on highways produces dioxin or other pollutants. Dioxin is just one of many chemicals that similarly activate this pathway," says Holoshitz.

Dioxin also has been shown to increase severity in an experimental model of another autoimmune disease, multiple sclerosis.

SEE ALSO: 'Master Regulator' May Make Women More Susceptible to Autoimmune Diseases

"We've shown in this study that the interaction between dioxin and the HLA gene variant activates events known to be associated with rheumatoid arthritis. And we've demonstrated quite convincingly that this facilitates bone destruction," says Holoshitz.

Bone degeneration in rheumatoid arthritis is caused by hyperactivity of certain bone cells called osteoclasts, which absorb bone tissue. "In our research with the combination of dioxin and the HLA gene variant, we saw that osteoclasts are overactive and overabundant, and that bone is destroyed because of it," says Holoshitz.

Currently, the treatments available for rheumatoid arthritis focus primarily on the inflammation but do not directly target bone destruction, says Holoshitz. "Once we have better drugs that directly and specifically address bone destruction in this disease, we'll have better treatment."

Says Holoshitz: "As a separate project, we have a couple of early-stage drug candidates that block the HLA gene-activated pathway and are effective in preventing bone damage. These drugs almost completely inhibit experimental rheumatoid arthritis and bone damage in mice.

"By understanding the mechanisms, we may be able to develop better inhibitors to prevent disease and identify therapeutic targets for new treatment strategies," says Holoshitz.

Disclosure: Joseph Holoshitz, M.D., and Song Ling are inventors of technology owned by the University of Michigan and licensed to Cadila Healthcare Limited.


More Articles About: Lab Report Arthritis Rheumatology
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories two hands doctor patient yellow
Health Lab
Study: Older adults with rheumatoid arthritis still undermedicated, despite aggressive guidelines
Research shows adults with rheumatoid arthritis are underprescribed disease-modifying drugs, despite guidelines saying otherwise. Clinicians must treat rheumatic diseases while addressing multimorbidity and polypharmacy.
auto immune image
Health Lab
Exploring New Treatments for Autoimmune Diseases
A new grant will allow Michigan Medicine researchers to explore personalized approaches to treating autoimmune diseases such as scleroderma, lupus, rheumatoid arthritis and others.
Illustration of a microscope
Health Lab
Helpful enzymes vanish in many patients with antiphospholipid syndrome
Researchers recently revealed a new mechanism behind antiphospholipid syndrome that the investigators hope will eventually allow treatments to be targeted closer to the source of the problem.
Woman sleeping on a couch holds her stomach, as if in pain
Health Lab
Long COVID-19 is linked to chronic pain conditions
Therapies for pain conditions like fibromyalgia provide clues for helping those with long COVID-19
vial of blood in container lab blue yellow grainy graphic
Health Lab
Unveiling potential diagnostic, treatment target for APS-related thrombocytopenia
Researchers at the University of Michigan Health have unveiled a new mechanism that drives thrombocytopenia and a potential clinically actionable biomarker for antiphospholipid syndrome associated thrombocytopenia.
Illustration of hand and enzymes that affect scleroderma patients
Health Lab
Novel antibody targets CD38 enzyme to treat systemic sclerosis
New study has identified an enzyme contributing to systemic sclerosis.